Abstract
Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Central Nervous System Agents in Medicinal Chemistry
Title:Genetics in Neural Toxicities of Drugs
Volume: 12 Issue: 4
Author(s): Da-Yong Lu, Ting-Ren Lu and Peng-Peng Zhu
Affiliation:
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Abstract: Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Export Options
About this article
Cite this article as:
Lu Da-Yong, Lu Ting-Ren and Zhu Peng-Peng, Genetics in Neural Toxicities of Drugs, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (4) . https://dx.doi.org/10.2174/187152412803760591
DOI https://dx.doi.org/10.2174/187152412803760591 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology Synthesis of Hitherto Unknown 4,4-Bis(methylthio)but-3-en-2-one-1,1,1,3- d4 and Its Application as 1,3-Dielectrophilic Building Block for the Synthesis of Deuterated Heterocycles and Aromatics
Letters in Organic Chemistry Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry APP-Based Neuroprotective Strategies
Current Alzheimer Research Defining the earliest pathological changes of Alzheimer’s disease
Current Alzheimer Research Mean Platelet Volume During Ischemic Stroke is a Potential Pro-inflammatory Biomarker in the Acute Phase and During Neurorehabilitation Not Directly Linked to Clinical Outcome
Current Neurovascular Research PDE-5 Inhibitors: Clinical Points
Current Drug Targets Control and Role of Plateau Potential Properties in the Spinal Cord
Current Pharmaceutical Design Cerebral Hypoperfusion During Carotid Artery Stenosis can Lead to Cognitive Deficits that may be Independent of White Matter Lesion Load
Current Neurovascular Research Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
CNS & Neurological Disorders - Drug Targets Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Prediction of Comparative Inhibition Efficiency for a Novel Natural Ligand, Galangin Against Human Brain Acetylcholinesterase, Butyrylcholinesterase and 5-Lipoxygenase: A Neuroinformatics Study
CNS & Neurological Disorders - Drug Targets Opioids in Neuropathic Pain
Current Pharmaceutical Design Genetic Association Analysis of NOS1 and Methamphetamine-Induced Psychosis Among Japanese
Current Neuropharmacology Neuregulin Signaling in Pieces-Evolution of the Gene Family
Current Pharmaceutical Design The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Joint Occurrence of Pain and Sleep Disturbances in People with Dementia. A Systematic Review
Current Alzheimer Research Nonfatal Suicidal Overdose of Olanzapine in an Adolescent
Current Drug Safety